Depression in Parkinson's disease: Conceptual issues and clinical challenges

Journal of Geriatric Psychiatry and Neurology

Volumn 17, Issue 3, 2004, Pages 120-126

  Leentjens, Albert F G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Depression; Parkinson's disease

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; MONOAMINE OXIDASE A INHIBITOR; NORTRIPTYLINE; PLACEBO; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AUTONOMIC DYSFUNCTION; CLINICAL TRIAL; COGNITION; DAILY LIFE ACTIVITY; DEPRESSION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; ELECTROCONVULSIVE THERAPY; HALLUCINOSIS; HUMAN; HYPERTHERMIA; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MUSCLE HYPERTONIA; MYOCLONUS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREMOR;

ACTIVITIES OF DAILY LIVING; DEPRESSION; EVIDENCE-BASED MEDICINE; HUMANS; INCIDENCE; PARKINSON DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

EID: 4344627571     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/0891988704267456     Document Type: Review

References (85)

1. Marsh L. Neuropsychiatric aspects of Parkinson's disease. Psychosomatics 2000; 41:15-23.
2. Hornykiewicz O. Brain neurotransmitter changes in Parkinson's disease. In: Marsden CD, Fahn S, Eds. Movement disorders. London: Butterworths, 1982:41-58.
3. Jellinger K. An overview of morphological changes in Parkinson's disease. Adv Neurol 1986; 45:1-18.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
5. Leentjens AFG, Verhey FRJ. Depression and Parkinson's disease: a conceptual challenge. Acta Neuropsychiatrica 2002; 14:147-151.
6. Price BH, Adams RD, Coyle JT. Neurology and psychiatry: closing the great divide. Neurology 2000; 54:8-14.
7. Goodman A. Organic unity theory: the mind-body problem revisited. Am J Psychiatry 1991; 148:553-563.
8. Kandel ER. A new intellectual framework for psychiatry. Am J Psychiatry 1998; 155:457-470.
9. Schiffer RB, Kurlan R, Rubin A, Boer S. Evidence for atypical depression in Parkinson's disease. Am J Psychiatry 1988; 145:1020-1022.
10. Menza MA, Robertson-Hoffman DE, Banapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993; 34:465-470.
11. Henderson R, Kurlan R, Kersun JM, Como P. Preliminary examination of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4:257-264.
12. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease, a quantitative and qualitative approach. J Neurol Neurosurg Psychiatry 1986; 49:381-389.
13. Brown RG, MacCarthy B, Gotham AM, Der GJ, Marsden CD. Depression and disability in Parkinson's disease: a follow-up of 132 cases. Psychol Med 1988; 49:381-389.
14. Huber SJ, Freidenberg DL, Paulson GW, Shuttleworth CJA. The pattern of depressive symptoms varies with progression of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53:257-258.
15. Leentjens AFG, Marinus J, Van Hilten JJ, et al. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease: a discriminant analytic approach. J Neuropsychiatry Clin Neurosci 2003; 15:74-77.
16. Hantz P, Cardoc-Davies G, Cardoc-Davies T, et al. Depression in Parkinson's disease. Am J Psychiatry 1994; 151:1010-1014.
17. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease; a community based study. Arch Neurol 1996; 53:175-179.
18. Beekman ATF, Copeland JRM, Prince MJ. Review of community prevalence of depression in later life. Br J Psychiatry 1999; 174:307-311.
19. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 149:443-454.
20. Hoogendijk WJG, Sommer IEC, Tissingh G, et al. Depression in Parkinson's disease; the impact of symptom overlap on prevalence. Psychosomatics 1998; 39:416-421.
21. Naarding P, Leentjens AFG, Van Kooten F, Verhey FRJ. Disease-specific properties of the Hamilton rating scale for depression (HAMD) in patients with stroke, Alzheimer's dementia and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002; 14:329-334.
22. Weintraub D, Moberg PJ, Duda JE, et al. Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatr Neurol 2003; 16:178-183.
23. Leentjens AFG, Van den Akker M, Metsemakers JFM, et al. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003; 18:414-418.
24. Schuurman AG, Van den Akker M, Ensinck KTJL, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002; 58:1501-1504.
25. Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 2001; 104:380-386.
26. Buntinx F, Kester A, Bergers J, Knottnerus JA. Is depression in the elderly followed by dementia? A retrospective cohort study based in clinical practice. Age Ageing 1996; 25:231-233.
27. McGee R, Williams S, Elwood M. Depression and the development of cancer: a meta-analysis. Soc Sci Med 1994; 38:187-192.
28. Hemingway H, Marmot M. Evidence based cardiology: Psychosocial factors in the aetiology and prognosis of coronary heart disease: systematic review of prospective cohort studies. Br Med J 1999; 318:1460-1467.
29. Wassertheil-Smoller S, Applegate WB, Berge K, et al. Change in depression as a precursor of cardiovascular events. Arch Int Med 1996; 156:553-561.
30. McEwen BS. Mood disorders and allostatic load. Biol Psychiatry 2003; 54:200-207.
31. Leentjens AFG, Lousberg R, Verhey FRJ. Markers for depression in Parkinson's disease. Acta Psychiatr Scand 2002; 106:196-201.
32. Cole SA, Woodard JL, Juncos JL, et al. Depression and disability in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996; 8:20-25.
33. Santamaria J, Tolosa ES, Valles A, et al. Mental depression in untreated Parkinson's disease of recent onset. Adv Neurol 1986; 45:443-446.
34. Schrag A, Jahanshabi M, Quinn NP. What contributes to depression in Parkinson's disease? Psychol Med 2001; 31:65-73.
35. Starkstein S, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J Nerv Ment Dis 1990; 178:27-31.
36. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings J. Risk factors for depression in Parkinson's disease. Arch Neurol 1997; 54:625-630.
37. Holthoff VA, Beurhien-Baumann B, Pietrzyk U, et al. Changes in regional cerebral perfusion in depression. SPECT monitoring of response to treatment. Nervenarzt 1999; 70:620-626.
38. Klemm E, Danos P, Grunwald F, et al. Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression: a study with single photon emission computed tomography. Psychiatry Res 1996; 68:1-10.
39. Chemerinski E, Robinson RG. The neuropsychiatry of stroke. Psychosomatics 2000; 41:5-14.
40. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10:399-406.
41. Corrigan MH, Denehan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11:58-65.
42. De Battista C, Solvason HB, Heilig Breen JA, Schatzberg AF. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol 2000; 20:274-275.
43. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced states. In: Weiner WJ, Lang AE, eds. Behavioural neurology of movement disorders. Advances in neurology. Vol. 65. New York: Raven, 1995:115-138.
44. Mayeux R, Stern Y, Cote L, Williams BW. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984; 34:642-646.
45. Mayeux R. The "serotonergic hypothesis" for depression in Parkinson's disease. Adv Neurol 1990; 53:163-166.
46. Van Praag HM, De Haen S. Central serotonergic metabolism and frequency of depression. Psychiatr Res 1979; 1:219-224.
47. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57:449-454.
48. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998; 32:692-698.
49. Fibiger HC. The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Can J Neurol Sci 1984; 11:105-107.
50. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972; ii:632-635.
51. Burt T, Sachs GS, Demopulos C. Donepezil in treatment-resistant bipolar disorder. Biol Psychiatry 1999; 45:959-964.
52. Van Praag HM, Asnis GM, Kahn RS. Monoamines and abnormal behaviour: a multi-aminergic perspective. Br J Psychiatry 1990; 157:723-734.
53. Riederer P, Birkmayer W. A new concept: brain area specific imbalance of neurotransmitters in depression syndrome: human brain studies. In: Usdin E, Sourkes TL, Youdim MBH, eds. Enzymes and neurotransmitters in mental disease. New York: John Wiley, 1980:261-279.
54. Birkmayer W, Danielczy W, Neumayer E, Riederer P. The balance of biogenic amines as condition for normal behaviour. J Neural Trans 1972; 33:38-45.
55. Brown R, Jahanshahi M. Depression in Parkinson's disease: a psychosocial viewpoint. In: Weiner J, Lang AE, eds. Behavioral neurology of movement disorders. Advances in neurology. Vol. 65. New York: Raven, 1995:61-84.
56. Ardouin C, Pillon B, Pfeiffer E, et al. Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol 1999; 46:217-223.
57. Martinez-Martin P, Valldeoriola F, Tolosa E, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Mov Disord 2002; 17:372-377.
58. Krack P, Kumar R, Ardouin C, et al. Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord 2001; 16:867-875.
59. Romito LM, Raja M, Daniele A, et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord 2002; 17:1371-1374.
60. Kulisevsky J, Berthier ML, Gironel A, et al. Mania following deep brain stimulation for Parkinson's disease. Neurology 2002; 59:1421-1424.
61. Bejjani BP, Arnulf I, Thivard L, et al. Transient acute depression by high-frequency deep-brain stimulation. N Engl J Med 1999; 340:1476-1480.
62. Stefurak T, Mikulis D, Mayberg M, et al. Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI case study. Mov Disord 2003; 18:1499-1507.
63. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003; 65:193-207.
64. Hobson P, Holden A, Meara J. Measuring the impact of Parkinson's disease with the Parkinson's Disease Quality of Life questionnaire. Age Ageing 1999; 28:341-346.
65. Liu CY, Wang SJ, Fuh JL, et al. The correlation of depression with functional ability in Parkinson's disease. J Neurol 1997; 244:493-498.
66. American Psychiatric Association. Practice guideline for major depressive disorder in adults. American Psychiatric Association practice guidelines for the treatment of psychiatric disorder. Washington, DC: American Psychiatric Association, 2000:413-495.
67. Klaassen T, Verhey FRJ, Sneijders GHJM, et al. Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 1995; 7:281-286.
68. Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson's disease treated with citalopram. Nord J Psychiatry 1998; 52:163-169.
69. Leentjens AFG, Vreeling FW, Luijckx GJ, Verhey FRJ. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry 2003; 18:552-554.
70. Andersen J, Aabro ENG, Hjelmsted A, Pedersen HE. Anti-depressive treatment in Parkinson's disease; a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. Acta Neurol Scand 1980; 62:210-219.
71. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology 1984; 34:1092-1094.
72. Leentjens AFG, Verhey FRJ, Vreeling FW. Een depressieve patiente met de ziekte van Parkinson succesvol behandeld met buproprion. Ned Tijdschr Geneeskd 2000; 144:2157-2159.
73. Howard WT, Warnock JK. Bupropion-induced psychosis. Am J Psychiatry 1999; 156:2017-2018.
74. Moellentine C, Rummans T, Ahlskog JE, et al. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci 1998; 10:187-193.
75. Leentjens AFG, Van den Broek WW, Vreeling FW, Honig A. Electroconvulsietherapie (ECT) als behandelmogelijkheid voor motorische symptomen van M.Parkinson. Acta Neuropsychiatrica 1998; 10:22-26.
76. Andersen K, Balldin J, Gottfries CG, et al. A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena. Acta Neurol Scand 1987; 76:191-199.
77. Pridmore S, Yeo PT, Pasha MI. Electroconvulsive therapy for the physical signs of Parkinson's disease without depressive disorder. J Neurol Neurosurg Psychiatry 1995; 58:641-642.
78. Pridmore S, Pollard C. Electroconvulsive therapy in Parkinson's disease: a 30 month follow-up. J Neurol Neurosurg Psychiatry 1996; 61:693.
79. Movement Disorder Society Task Force. Treatment of depression in idiopathic Parkison's disease. Mov Disord 2002; 17(suppl 4):S112-S119.
80. Ghazi-Noori S, Chung TH, Deane KHO, et al. Therapies for depression in Parkinson's disease. The Cochrane Library. Vol. 1. Chichester, UK Wiley, 2004.
81. Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor function during placebo treatment in PD. Neurology 2000; 54:710-714.
82. De la Fuente-Fernández R, Ruth TJ, Sossi V, et al. Expectation of dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293:1164-1166.
83. Olanow CW, Koller WC. An algorithm for the treatment of Parkinson's disease. Neurology 1998; 50(suppl 3):S1-S57.
84. Gonul AS, Aksu M. SSRI-induced parkinsonism maybe an early sign of future Parkinson's disease. J Clin Psychiatry 1999; 60:410.
85. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of eldepryl and an antidepressant in Parkinson's disease. Neurology 1997; 48:1070-1077.